Policy
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Overnight, U.K. health authorities authorized the COVID-19 vaccine developed by AstraZeneca and Oxford University for emergency use.
Operation Warp Speed succeeded on the development component but is failing in the early stages of distribution. Here’s everything you need to know about it.
The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.
The agency placed the hold on the Astellas company’s trial after two patients died in the trial.
The United Kingdom is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.
In October, the FDA placed a clinical hold on the company’s Huntington’s disease gene therapy before that asset could make its way into the clinic.
Yesterday it was reported that the two companies were working to make more of their vaccine than the 1.3 billion it promised to manufacture in 2021.
Former U.S. Rep. Chris Collins spent less than a year in federal prison for pleading guilty to violating felony insider trading laws when he sat on the board of directors of Innate Therapeutics. On Tuesday, Collins received a pardon from President Donald Trump.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.
The U.S. Food and Drug Administration has approved several drugs and medical devices in the last week. Here’s a look.